IGM Biosciences, Inc. (IGMS)

Market Cap	580.67M
Revenue (ttm)	2.92M
Net Income (ttm)	-219.84M
Shares Out	59.46M
EPS (ttm)	-3.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	204,686
Open	9.35
Previous Close	9.54
Day's Range	9.26 - 10.08
52-Week Range	4.72 - 22.50
Beta	0.19
Analysts	Hold
Price Target	14.63 (+49.82%)
Earnings Date	Nov 8, 2024

About IGMS

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 prote...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2019
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: IGMS
• Website: https://igmbio.com

Financial Performance

In 2023, IGM Biosciences's revenue was $2.13 million, an increase of 99.25% compared to the previous year's $1.07 million. Losses were -$246.42 million, 11.4% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for IGMS stock is "Hold." The 12-month stock price forecast is $14.63, which is an increase of 49.82% from the latest price.

Price Target

$14.63

(49.82% upside)

Analyst Consensus: Hold